The FDA has approved Procysbi (cysteamine bitartrate; Horizon Therapeutics) delayed-release oral granules, a new formulation for the treatment of nephropathic cystinosis in patients aged 1 year and older.
In a randomized, placebo-controlled trial that enrolled patients with chronic kidney disease stages 3 and 4, sodium bicarbonate did not significant affect sit-to-stand time or bone mineral density.
The Mediterranean Diet was picked as the best diet overall for 2020, according to new rankings released by US News and World Report. An expert panel assessed 35 diets to come up with the final results, examining the evidence behind each diet’s claims. Specifically, they evaluated the likelihood of short-term and long-term weight loss, how…
Full study results will be presented at an oral plenary session at the OxalEurope International Congress on Tuesday, March 31, 2020.
The FDA has accepted for review the New Drug Application (NDA) for veverimer (TRC101; Tricida) for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).
In a study of Swedish twins, investigators worked out the relative effects of genes and the environment on the correlation between metabolic syndrome and chronic kidney disease.
In a large study of patients with chronic kidney disease, metabolic acidosis independently increased the risk of progressing to end-stage renal disease and death.
Over 12 weeks, 59% of patients taking the hydrochloric acid binder achieved an increase or normalization in serum bicarbonate.
For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk
Men with metabolic syndrome or a smoking history had more than triple the risks for persistent moderate to severe nocturia after TURP.
